RECORMON® 4 000 IU/0,3 Mℓ INJECTION

Indications

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Hypertension
• Heart Failure
• Cardiac Arrhythmias

Dosage

Children: Refer to the BNF for Children for appropriate dosing

Adults: Refer to the BNF for specific dosing guidelines based on the condition being treated and the formulation of the drug used.

Mechanism of action

Beta-adrenergic agonists stimulate beta-adrenergic receptors, leading to increased intracellular cAMP levels, which causes relaxation of bronchial smooth muscle and dilation of the airways. This mechanism is particularly important in the treatment of asthma and COPD, where airway constriction is a major issue. Beta-blockers, on the other hand, inhibit the effects of catecholamines on beta receptors, resulting in decreased heart rate and myocardial contractility, which is beneficial in managing hypertension and certain types of cardiac arrhythmias.

Pharmacodynamics

The pharmacodynamics of beta drugs vary depending on whether they are agonists or antagonists. Agonists lead to a dose-dependent bronchodilation and increased heart rate, while antagonists decrease heart rate and myocardial oxygen demand. The effects of these drugs can be influenced by patient-specific factors such as receptor sensitivity, presence of comorbid conditions, and concurrent medications.

Pharmacokinetics

The pharmacokinetics of beta drugs can differ substantially. Agonists are typically rapidly absorbed and distributed, with onset of action occurring within minutes. They may have short half-lives, necessitating multiple doses throughout the day. Beta-blockers, in contrast, may have longer half-lives and can be administered once or twice daily. Metabolism usually occurs in the liver, and renal excretion is common for both classes, affecting their dosing in patients with renal impairment.

Interactions

• betablockers, selective + aminophylline: Severe (increases risk of bronchospasm)
• dacomitinib + betablockers, selective: Severe (increases exposure)
• mexiletine + betablockers, selective: Severe (increases risk of cardiovascular adverse effects)
• betablockers, selective + theophylline: Severe (increases risk of bronchospasm)
• beta 2 agonists + linezolid: Severe (increases risk of elevated blood pressure)
• mao-b inhibitors + beta: Severe (increases risk of severe hypertension)
• verapamil + betablockers, non-selective: Severe (increases risk of cardiovascular adverse effects)
• cobicistat + beta: Severe (increases exposure)
• dacomitinib + betablockers, non-selective: Severe (increases exposure)
• idelalisib + beta: Severe (increases exposure)

Indications

• Anemia of chronic kidney disease
• Anemia associated with cancer chemotherapy
• Anemia in patients undergoing major surgery
• Anemia in patients with HIV receiving zidovudine

Dosage

Children: Refer to the BNF for Children for specific pediatric dosing information.

Adults: Refer to the BNF for specific dosing guidelines based on the condition being treated.

Mechanism of action

Epoetin binds to the erythropoietin receptor on erythroid progenitor cells in the bone marrow, promoting their differentiation and proliferation. This action stimulates erythropoiesis, leading to increased production of RBCs. Additionally, it enhances the survival of erythroid progenitor cells and promotes the release of reticulocytes into the bloodstream, ultimately leading to an increase in hemoglobin levels.

Pharmacodynamics

Epoetin exhibits dose-dependent effects on erythropoiesis. Its activity results in increased hemoglobin concentration and hematocrit levels. The onset of action is generally observed within a few days, with peak effects typically seen within 1 to 2 weeks of administration. Long-term use may lead to increased RBC mass and improved oxygen delivery to tissues.

Pharmacokinetics

Epoetin is administered via subcutaneous or intravenous routes. It has a half-life of approximately 4 to 13 hours, depending on the formulation and route of administration. The drug is primarily eliminated through the kidneys, with a significant portion undergoing metabolic degradation. The pharmacokinetics may be influenced by factors such as renal function and patient-specific characteristics.

Contra-indications

• Uncontrolled hypertension
• Pure red cell aplasia
• Hypersensitivity to epoetin or any of its components

Adverse effects

• Hypertension
• Headache
• Fatigue
• Nausea
• Diarrhea
• Injection site reactions
• Thrombotic events (e.g., stroke, myocardial infarction)

Interactions

• Antihypertensive agents may require dose adjustments due to the potential for increased blood pressure
• Iron supplements may be used concurrently; ensure adequate iron stores for optimal erythropoiesis

Precautions

• Monitor hemoglobin levels regularly to avoid excessive increases
• Use with caution in patients with a history of cardiovascular disease
• Assess iron status before and during treatment

Pregnancy

Epoetin may be used during pregnancy if the benefits outweigh the risks, as it is classified as category C.

Breast-feeding

Epoetin is excreted in breast milk; caution is advised when administered to nursing mothers.

Storage

Store in the refrigerator (2°C to 8°C), do not freeze. Keep protected from light.

Formulations

• Epoetin alfa injectable solution
• Epoetin beta injectable solution